Holen Sie sich die Stockscreener-App
110.83
1.60%
1.75
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$109.08
Offen:
$110.1
24-Stunden-Volumen:
9.91M
Relative Volume:
1.19
Marktkapitalisierung:
$192.72B
Einnahmen:
$44.33B
Nettoeinkommen (Verlust:
$6.48B
KGV:
29.93
EPS:
3.7033
Netto-Cashflow:
$6.92B
1W Leistung:
+1.40%
1M Leistung:
-13.26%
6M Leistung:
-15.35%
1J Leistung:
-13.56%
1-Tages-Spanne:
$108.95
$111.06
1-Wochen-Bereich:
$106.25
$111.06
52-Wochen-Spanne:
$105.27
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
110.83 | 189.68B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
358.29 | 138.60B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
102.90 | 131.98B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
76.27 | 115.14B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.71 | 45.32B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Abbott Laboratories (ABT): Short-Term Headwinds, Strategic Pipeline Strength, and UBS Buy Rating - Finviz
Abbott stock price: what to watch Monday after FDA Libre recall update, insider buy - TechStock²
Analysts’ Top Healthcare Picks: Mettler-Toledo (MTD), Abbott Laboratories (ABT) - The Globe and Mail
Top Abbott Insider Quietly Makes a Bold Million-Dollar Move - TipRanks
Abbott Labs CEO makes $2M bet as stock sinks - thestreet.com
Abbott Laboratories Announces Measurable Results From LATAM Diagnostic Market Development and Training Initiative Led by Claudia Marcela Riaño Caro - PRWeb
Exact Sciences (EXAS) Advances as HSR Period Expires for Abbott Deal - GuruFocus
Abbott studies support pulsed field ablation, dual ablation catheters - MassDevice
Abbott Stock: 2026 Recovery Outlook After a 17% Decline - TIKR.com
Abbott (ABT) Showcases Promising AFib Therapy Advances at Boston Symposium - GuruFocus
Abbott reports positive results from study on its atrial fibrillation therapies - AlphaStreet News -
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance Singapore
Abbott’s atrial fibrillation treatments show strong results in new studies By Investing.com - Investing.com India
Abbott Labs director Starks buys shares worth $1.08 million By Investing.com - Investing.com India
Catheter trials show Abbott devices cut AFib episodes for most patients - stocktitan.net
UK’s NICE recommends Abbott’s Cardiomems heart failure system - BioWorld MedTech
Abbott on track with dual sensor, FDA warns on FreeStyle Libre - Modern Healthcare News
BTIG Reaffirms Their Buy Rating on Abbott Laboratories (ABT) - The Globe and Mail
US FDA says injuries from Abbott’s recalled glucose sensors reach 860 - WHTC
Abbott Laboratories: How a 136-Year-Old Medtech Giant Is Re?Engineering the Future of Diagnostics an - AD HOC NEWS
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
US FDA says injuries from Abbott's recalled glucose sensors reach 860 - marketscreener.com
Abbott recalls glucose sensors after seven deaths linked to faulty readings - marketscreener.com
Abbott Laboratories (ABT) Faces FDA's Most Serious Recall Over G - GuruFocus
Abbott glucose monitor recall classified as most serious (ABT) - Seeking Alpha
Do Wall Street Analysts Like Abbott Laboratories Stock? - Barchart.com
FDA demands better response from Abbott over Libre inspection violations - Fierce Biotech
Hantz Financial Services Inc. Sells 29,746 Shares of Abbott Laboratories $ABT - MarketBeat
Envestnet Asset Management Inc. Sells 169,808 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock Now 18% Cheaper, Time To Buy - Trefis
Gains Report: Can Abbott Laboratories sustain earnings growthDay Trade & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Abbott receives FDA warning letter related to FreeStyle Libre CGMs - MassDevice
2 Healthcare Dividend Stocks That are Just What the Doctor Ordered - The Motley Fool
Abbott Faces FDA Scrutiny On FreeStyle Libre And Broader Quality Story - Yahoo Finance
Abbott (ABT) stock slips on FDA warning letter over FreeStyle Libre testing; dates to watch - TechStock²
Abbott CEO Share Purchase Highlights $21b Exact Sciences Deal And Valuation - simplywall.st
Abbott receives FDA warning letter over Freestyle Libre CGMs - MedTech Dive
Abbott (ABT) Faces Profit Headwinds as Pediatric Nutrition Remains Under Pressure - Finviz
OTC/DTC Infectious Disease Diagnostics Research Report 2026: Market Strategies, Trends, and Forecasts 2025-2029 - GlobeNewswire Inc.
Sollinda Capital Management LLC Sells 15,866 Shares of Abbott Laboratories $ABT - MarketBeat
Jones Financial Companies Lllp Buys 61,627 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Stake Lessened by Thrivent Financial for Lutherans - MarketBeat
Abbott Laboratories (ABT): A Bull Case Theory - Insider Monkey
Abbott (ABT) Sees Increased Bearish Options Activity - GuruFocus
Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date - TechStock²
Abbott’s Exact Sciences Deal Recasts Diagnostics While Nutrition Faces Reset - Yahoo Finance
Abbott stock price today: ABT slips after Barclays cuts target as Wall Street resets expectations - TechStock²
The Best Dividend King to Buy With $150 - AOL.com
ABT: Barclays Adjusts Abbott Laboratories Price Target to $142 | - GuruFocus
Abbott Laboratories (NYSE:ABT) Price Target Cut to $142.00 by Analysts at Barclays - MarketBeat
Abbott: Long-Term Investment Opportunity For Dividend Growth Investors - Seeking Alpha
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.14%
0.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):